However, with the removal of sensitive cells at the initial stage of treatment, surviving tumor cells activate prosurvival pathways such as NF‐κB and HIF‐1α through epigenetic modifications (e.g., histone deacetylation), which in turn affects tumor drug resistance [205]. This evidence concerns the gene HIF1A and neoplasm.